Carboxypeptidase which converts angiotensin I to angiotensin 1-9, a peptide of unknown function, and angiotensin II to angiotensin 1-7, a vasodilator. Also able to hydrolyze apelin- 13 and dynorphin-13 with high efficiency. May be an important regulator of heart function. In case of human coronaviruses SARS and HCoV-NL63 infections, serve as functional receptor for the spike glycoprotein of both coronaviruses. Interacts with ITGB1. Interacts with SARS-CoV and HCoV- NL63 spike glycoprotein. Up-regulated in failing heart. Expressed in endothelial cells from small and large arteries, and in arterial smooth muscle cells. Expressed in lung alveolar epithelial cells, enterocytes of the small intestine, Leydig cells and Sertoli cells. Expressed in heart, kidney, testis, and gastrointestinal system. Activated by chloride and fluoride, but not bromide. Inhibited by MLN-4760, cFP_Leu, and EDTA, but not by the ACE inhibitors linosipril, captopril and enalaprilat. Belongs to the peptidase M2 family. 2 isoforms of the human protein are produced by alternative splicing. Note: This description may include information from UniProtKB.
Protein type: EC 126.96.36.199; Protease; Membrane protein, integral
Cellular Component: extracellular space; cell surface; cytoplasm; extracellular region; integral to membrane; plasma membrane; lipid raft
Molecular Function: peptidyl-dipeptidase activity; viral receptor activity; protein binding; carboxypeptidase activity; zinc ion binding; metallopeptidase activity; endopeptidase activity; glycoprotein binding
Biological Process: virion attachment, binding of host cell surface receptor; entry of virus into host cell; regulation of vasodilation; angiotensin maturation; regulation of systemic arterial blood pressure by renin-angiotensin; tryptophan transport; regulation of cytokine production; regulation of cell proliferation; cellular protein metabolic process; regulation of vasoconstriction; regulation of inflammatory response; angiotensin catabolic process in blood; receptor biosynthetic process; angiotensin mediated drinking behavior
LTP: The number of records in which this modification site was determined using site-specific methods. SS methods include amino acid sequencing, site-directed mutagenesis, modification site-specific antibodies, specific MS strategies, etc.